Kai Wang

发表

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing

Alex M. Fichtenholtz, James X. Sun, M. Rubin, 2013, Nature Biotechnology.

Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets.

R. Yelensky, J. Ross, M. Cronin, 2014, Cancer discovery.

Biliary cancer: Utility of next‐generation sequencing for clinical management

P. Stephens, H. Kang, V. Miller, 2016, Cancer.

A High Frequency of Activating Extracellular Domain ERBB2 (HER2) Mutation in Micropapillary Urothelial Carcinoma

Kai Wang, Timothy A Jennings, Doron Lipson, 2013, Clinical Cancer Research.

Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets

David M. Jones, P. Stephens, R. Yelensky, 2015, Journal of Clinical Pathology.

ComprehensiveGenomicProfilingofAdvancedEsophagealSquamous CellCarcinomasandEsophagealAdenocarcinomasRevealsSimilarities and Differences

P. Stephens, R. Yelensky, J. Ross, 2015 .

Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance

L. Garraway, X. Mu, R. Yelensky, 2017, Science Translational Medicine.

Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms

S. Armstrong, P. Stephens, R. Yelensky, 2014, Proceedings of the National Academy of Sciences.

Comprehensive Genomic Profiling Identifies Frequent Drug-Sensitive EGFR Exon 19 Deletions in NSCLC not Identified by Prior Molecular Testing

P. Stephens, R. Yelensky, S. Ou, 2016, Clinical Cancer Research.

Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study

P. Stephens, V. Miller, D. Khaira, 2016, Breast Cancer Research and Treatment.

Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary

D. Lipson, V. Miller, Siraj M. Ali, 2014, Case Reports in Oncology.

LYMPHOID NEOPLASIA Integrated genomic DNA/RNA pro ﬁ ling of hematologic malignancies in the clinical setting

Alex M. Fichtenholtz, S. Armstrong, P. Stephens, 2016 .

Association of PIK3CA mutation with response (ExRx) to cetuximab (C) in metastatic (met) triple-negative breast cancer (TNBC).

C. Horak, N. Palma, Kai Wang, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors

S. Mallal, R. Yelensky, S. Loi, 2015, Clinical Cancer Research.

Comprehensive Genomic Profiling of Relapsed and Metastatic Adenoid Cystic Carcinomas by Next-generation Sequencing Reveals Potential New Routes to Targeted Therapies

P. Stephens, R. Yelensky, D. Lipson, 2014, The American journal of surgical pathology.

Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations

P. Stephens, R. Yelensky, D. Lipson, 2016, Clinical Cancer Research.

Relapsed Classic E-Cadherin (CDH1)–Mutated Invasive Lobular Breast Cancer Shows a High Frequency of HER2 (ERBB2) Gene Mutations

James X. Sun, P. Stephens, R. Yelensky, 2013, Clinical Cancer Research.

Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence

R. Yelensky, H. Gómez, Jenny C. Chang, 2016, Science Translational Medicine.

The distribution of BRAF gene fusions in solid tumors and response to targeted therapy

Kai Wang, Doron Lipson, Roman Yelensky, 2015, International journal of cancer.

Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations

P. Stephens, V. Miller, D. Khaira, 2015, Breast Cancer Research and Treatment.

Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti‐HER2 targeted therapies

P. Stephens, R. Yelensky, R. Bose, 2016, Cancer.

Abstract P3-07-05: Non-amplification ERBB2 genomic alterations in 5,605 cases of refractory and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies

R. Yelensky, D. Lipson, V. Miller, 2016 .

Correlation Between Molecular Subclassifications of Clear Cell Renal Cell Carcinoma and Targeted Therapy Response.

P. Stephens, T. Ho, T. Choueiri, 2016, European urology focus.

Genomic Alterations Observed in Colitis-Associated Cancers Are Distinct From Those Found in Sporadic Colorectal Cancers and Vary by Type of Inflammatory Bowel Disease.

Zachary J. Heins, N. Schultz, R. Yantiss, 2016, Gastroenterology.

New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing.

David M. Jones, P. Stephens, R. Yelensky, 2014, The oncologist.

Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin.

P. Stephens, R. Yelensky, D. Lipson, 2015, The oncologist.

Relapsed classic E-cadherin (CDH1) mutated invasive lobular breast cancer demonstrates a high frequency of HER2 (ERBB2) gene mutations

James X. Sun, P. Stephens, R. Yelensky, 2013 .

Human Cancer Biology Relapsed Classic E-Cadherin ( CDH 1 ) – Mutated Invasive Lobular Breast Cancer Shows a High Frequency of HER 2 ( ERBB 2 ) Gene Mutations

James X. Sun, P. Stephens, R. Yelensky, 2013 .

Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences.

P. Stephens, R. Yelensky, D. Lipson, 2015, The oncologist.

Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies.

P. Stephens, R. Yelensky, S. Ou, 2015, The oncologist.

Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target

James X. Sun, P. Stephens, V. Miller, 2016, Clinical Cancer Research.

Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials.

P. Stephens, V. Miller, G. Frampton, 2016, The oncologist.

RICTOR Amplifi cation Defi nes a Novel Subset of Patients with Lung Cancer Who May Benefi t from Treatment with mTORC 1 / 2 Inhibitors

P. Stephens, R. Yelensky, D. Lipson, 2015 .

Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies.

Kai Wang, Roman Yelensky, Gary Palmer, 2015, JAMA oncology.

Genomic Profiling of T-Cell Neoplasms Reveals Frequent JAK1 and JAK3 Mutations With Clonal Evasion From Targeted Therapies

V. Miller, Y. Shyr, A. Greenplate, 2018, JCO precision oncology.

Genomic profiling of advanced-stage, metaplastic breast carcinoma by next-generation sequencing reveals frequent, targetable genomic abnormalities and potential new treatment options.

P. Stephens, R. Yelensky, D. Lipson, 2015, Archives of pathology & laboratory medicine.

Characterization of Clinical Cases of Collecting Duct Carcinoma of the Kidney Assessed by Comprehensive Genomic Profiling.

P. Stephens, R. Yelensky, E. V. Van Allen, 2016, European urology.

Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting.

Alex M. Fichtenholtz, S. Armstrong, P. Stephens, 2016, Blood.

Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias.

S. Armstrong, A. Ferrando, J. Teruya-Feldstein, 2015, Blood.

Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations.

P. Stephens, P. Tamboli, E. Jonasch, 2016, European urology.

Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors via GLI-mediated activation of KIT expression

J. Sicklick, O. Harismendy, M. Kendrick, 2016, Oncotarget.

Evaluation of 122 advanced‐stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies

P. Stephens, R. Yelensky, M. Mihm, 2016, Cancer.

Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy

Kai Wang, Doron Lipson, Roman Yelensky, 2014, Modern Pathology.

recurrent alterations in antiapoptotic and chromatin-remodeling genes Targeted genomic sequencing of pediatric Burkitt lymphoma identifies

M. Rubin, R. Yelensky, E. Cesarman, 2013 .

Targeted genomic sequencing of pediatric Burkitt lymphoma identifies recurrent alterations in antiapoptotic and chromatin-remodeling genes.

M. Rubin, P. Stephens, R. Yelensky, 2012, Blood.

BRAF in Lung Cancers: Analysis of Patient Cases Reveals Recurrent BRAF Mutations, Fusions, Kinase Duplications, and Concurrent Alterations.

S. Ganesan, M. Rosenzweig, S. Ou, 2018, JCO precision oncology.

Patient-derived xenotransplants can recapitulate the genetic driver landscape of acute leukemias

S. Armstrong, P. Stephens, R. Yelensky, 2016, Leukemia.

FGFR1 and NTRK3 actionable alterations in “Wild-Type” gastrointestinal stromal tumors

J. Sicklick, O. Harismendy, James D. Murphy, 2016, Journal of Translational Medicine.

Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma

James X. Sun, P. Stephens, R. Yelensky, 2016, Oncology.

Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations

P. Stephens, R. Yelensky, D. Lipson, 2016, Cancer.

A Combination of Targeted Therapy with Chemotherapy Backbone Induces Response in a Treatment-Resistant Triple-Negative MCL1-Amplified Metastatic Breast Cancer Patient

Siraj M. Ali, Kai Wang, Jon H. Chung, 2016, Case Reports in Oncology.

RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors.

Sanjay Goel, Kai Wang, Amit Verma, 2015, Cancer discovery.

Durable clinical benefit to trastuzumab and chemotherapy in a patient with metastatic colon adenocarcinoma harboring ERBB2 amplification

P. Stephens, R. Yelensky, Bahar Yilmazel, 2015, Oncoscience.

Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening

Joon-Oh Park, P. Stephens, J. Huh, 2015, Oncotarget.

Genomic alterations in DNA repair and chromatin remodeling genes in estrogen receptor-positive metastatic breast cancer patients with exceptional responses to capecitabine

R. Yelensky, J. O’Shaughnessy, J. Pippen, 2015, Cancer medicine.

N of 1 case reports of exceptional responders accrued from pancreatic cancer patients enrolled in first-in-man studies from 2002 through 2012

Sunil Sharma, Jian Ying, Kai Wang, 2015, Oncoscience.

A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice.

P. Stephens, R. Yelensky, L. Pusztai, 2014, The oncologist.

Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein

V. Miller, Siraj M. Ali, S. Westin, 2014, Journal of Hematology & Oncology.

Abstract 1893: A computational method for somatic versus germline variant status determination from targeted next-generation sequencing of clinical cancer specimens without a matched normal control

James X. Sun, P. Stephens, R. Yelensky, 2014 .

Abstract A23: Comprehensive next-generation sequencing-based genomic profiling identifies actionable genomic alterations in diverse pediatric tumor types: The Foundation Medicine (FMI) experience

P. Stephens, R. Yelensky, V. Miller, 2014 .

A case of advanced infantile myofibromatosis harboring a novel MYH10‐RET fusion

P. Stephens, M. Rosenzweig, V. Miller, 2017, Pediatric blood & cancer.

FGFR1 and NTRK3 actionable alterations in “Wild-Type” gastrointestinal stromal tumors

J. Sicklick, O. Harismendy, James D. Murphy, 2016, Journal of Translational Medicine.

Comprehensive genomic profiling of gallbladder adenocarcinoma and frequent genomic-derived targets of therapy.

G. Frampton, Siraj M. Ali, N. Palma, 2014 .

Exome Sequencing Identifies Early Gastric Carcinoma as an Early Stage of Advanced Gastric Cancer

Joon-Oh Park, S. Park, Seonwoo Kim, 2013, PloS one.

Identifying ALK rearrangements that are not detected by FISH with targeted next-generation sequencing of lung carcinoma.

R. Yelensky, S. Ou, D. Lipson, 2014 .

Comprehensive Genomic Profiling of Advanced Penile Carcinoma Suggests a High Frequency of Clinically Relevant Genomic Alterations.

P. Stephens, R. Yelensky, D. Lipson, 2016, The oncologist.

Unique genomic features in adolescent and young adult, as compared to older adult, non‐Hodgkin lymphoma and potential therapeutic targets

P. Stephens, R. Yelensky, D. Lipson, 2017, British journal of haematology.

Comprehensive genomic profiling of biliary tract cancers to reveal tumor-specific differences and frequency of clinically relevant genomic alterations.

P. Stephens, R. Yelensky, D. Lipson, 2015 .

Actionable Therapeutic Targets Breast Cancers after Neoadjuvant Chemotherapy Identifies Molecular Profiling of the Residual Disease of Triple-Negative

J. Giltnane, J. Balko, Kai Wang, 2014 .

Identification Of Actionable Genomic Alterations In Hematologic Malignancies By a Clinical Next Generation Sequencing-Based Assay

Alex M. Fichtenholtz, S. Armstrong, P. Stephens, 2013 .

Clinical next‐generation sequencing successfully applied to fine‐needle aspirations of pulmonary and pancreatic neoplasms

P. Stephens, R. Yelensky, D. Lipson, 2013, Cancer cytopathology.

Correction: RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors

S. Mallal, R. Yelensky, S. Loi, 2019, Clinical Cancer Research.

Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions.

P. Stephens, S. Ou, V. Miller, 2016, The oncologist.

Comprehensive genomic profiling of clinically advanced colorectal carcinoma to reveal frequent opportunities for targeted therapies.

P. Stephens, R. Yelensky, D. Lipson, 2015 .

Comprehensive genomic profiling of 443 cases of renal cell carcinoma to reveal frequent clinically relevant genomic alterations.

R. Yelensky, T. Choueiri, D. Lipson, 2015 .

Epidermal Growth Factor Receptor P753S Mutation in Cutaneous Squamous Cell Carcinoma Responsive to Cetuximab-Based Therapy.

V. Miller, B. Esmaeli, Siraj M. Ali, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comprehensive genomic profiling of solid tumors from 677 adolescents and young adults for revealing a distinct spectrum of targetable genomic alterations.

R. Yelensky, D. Lipson, V. Miller, 2014 .

Patient Derived Xenograft (PDX) Models Faithfully Recapitulate The Genetic Composition Of Primary AML

S. Armstrong, P. Stephens, R. Yelensky, 2013 .

319 Genomic profiling of uterine leiomyosarcomas reveal frequent alterations in Akt/mammalian target of rapamycin (mTOR) pathway genes and other actionable genomic abnormalities linked to targeted therapies

V. Miller, Siraj M. Ali, J. Elvin, 2014 .

Abstract S3-6: Profiling of triple-negative breast cancers after neoadjuvant chemotherapy identifies targetable molecular alterations in the treatment-refractory residual disease

R. Yelensky, M. Cronin, H. Gómez, 2012 .

Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder to reveal frequency of clinically relevant genomic alterations.

P. Stephens, R. Yelensky, D. Lipson, 2015 .

Use of next-generation sequencing (NGS) to identify actionable genomic alterations (GA) in diverse solid tumor types: The Foundation Medicine (FMI) experience with 2,200+ clinical samples.

R. Yelensky, D. Lipson, V. Miller, 2013 .

Comprehensive genomic profiling of biliary tract cancers to reveal tumor-specific differences and genomic alterations.

P. Stephens, R. Yelensky, D. Lipson, 2015 .

Correlation between findings from comprehensive genomic profiling and targeted therapy response in metastatic renal cell carcinoma.

P. Stephens, T. Ho, T. Choueiri, 2016 .

Unique genomic features in adolescent and young adult, as compared to older adult, non‐Hodgkin lymphoma and potential therapeutic targets

P. Stephens, R. Yelensky, D. Lipson, 2017, British journal of haematology.

Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance

L. Garraway, X. Mu, R. Yelensky, 2017, Science Translational Medicine.

Comprehensive genomic profiling of salivary mucoepidermoid carcinomas reveals frequent BAP1, PIK3CA, and other actionable genomic alterations

S. Karam, D. Raben, Siraj M. Ali, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice.

P. Stephens, R. Yelensky, L. Pusztai, 2014, The oncologist.